OBJECTIVE: To examine the relationship of blood pressure (BP) and use of angiotensin-receptor blocker or angiotensin-converting enzyme inhibitor to retinal vessel diameter in normotensive, normoalbuminuric persons with type 1 diabetes mellitus. METHODS: In a randomized, controlled clinical trial, clinic and 24-hour ambulatory BPs were measured in persons with type 1 diabetes mellitus and gradable fundus photographs both at baseline (n = 147) and at 5-year follow-up (n = 124). Retinal arteriole and venule diameters were measured by a computer-assisted technique. Individual arteriole and venule measurements were combined into summary indexes that reflect the average retinal arteriole (central retinal arteriole equivalent [CRAE]) and venule (central retinal venule equivalent [CRVE]) diameter of an eye, respectively. RESULTS: While controlling for age, study site, glycosylated hemoglobin level, and ambulatory pulse rate, the daytime ambulatory systolic (-0.29-microm effect per 1 mm Hg; P = .02), daytime ambulatory diastolic (-0.44-microm effect per 1 mm Hg; P = .04), nighttime ambulatory systolic (-0.27-microm effect per 1 mm Hg; P = .03), and 24-hour ambulatory systolic (-0.31-microm effect per 1 mm Hg; P = .03) BPs were cross-sectionally associated with a smaller CRAE. While controlling for age, study site, glycosylated hemoglobin level, ambulatory pulse rate, and baseline CRAE, no BP measure was associated with a change in CRAE or CRVE during 5 years of follow-up. Treatment with losartan potassium or enalapril maleate was not associated with a statistically significant change in CRAE or CRVE. CONCLUSION:Angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker therapy does not affect retinal arteriole or venule diameter in normotensive persons with type 1 diabetes mellitus. Trial Registration clinicaltrials.gov Identifier: NCT00143949.
RCT Entities:
OBJECTIVE: To examine the relationship of blood pressure (BP) and use of angiotensin-receptor blocker or angiotensin-converting enzyme inhibitor to retinal vessel diameter in normotensive, normoalbuminuric persons with type 1 diabetes mellitus. METHODS: In a randomized, controlled clinical trial, clinic and 24-hour ambulatory BPs were measured in persons with type 1 diabetes mellitus and gradable fundus photographs both at baseline (n = 147) and at 5-year follow-up (n = 124). Retinal arteriole and venule diameters were measured by a computer-assisted technique. Individual arteriole and venule measurements were combined into summary indexes that reflect the average retinal arteriole (central retinal arteriole equivalent [CRAE]) and venule (central retinal venule equivalent [CRVE]) diameter of an eye, respectively. RESULTS: While controlling for age, study site, glycosylated hemoglobin level, and ambulatory pulse rate, the daytime ambulatory systolic (-0.29-microm effect per 1 mm Hg; P = .02), daytime ambulatory diastolic (-0.44-microm effect per 1 mm Hg; P = .04), nighttime ambulatory systolic (-0.27-microm effect per 1 mm Hg; P = .03), and 24-hour ambulatory systolic (-0.31-microm effect per 1 mm Hg; P = .03) BPs were cross-sectionally associated with a smaller CRAE. While controlling for age, study site, glycosylated hemoglobin level, ambulatory pulse rate, and baseline CRAE, no BP measure was associated with a change in CRAE or CRVE during 5 years of follow-up. Treatment with losartan potassium or enalapril maleate was not associated with a statistically significant change in CRAE or CRVE. CONCLUSION: Angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker therapy does not affect retinal arteriole or venule diameter in normotensive persons with type 1 diabetes mellitus. Trial Registration clinicaltrials.gov Identifier: NCT00143949.
Authors: L D Hubbard; R J Brothers; W N King; L X Clegg; R Klein; L S Cooper; A R Sharrett; M D Davis; J Cai Journal: Ophthalmology Date: 1999-12 Impact factor: 12.079
Authors: W Gonzalez; V Fontaine; M E Pueyo; N Laquay; D Messika-Zeitoun; M Philippe; J F Arnal; M P Jacob; J B Michel Journal: Hypertension Date: 2000-07 Impact factor: 10.190
Authors: F de Nigris; F P D'Armiento; P Somma; A Casini; I Andreini; F Sarlo; G Mansueto; G De Rosa; D Bonaduce; M Condorelli; C Napoli Journal: Int J Cardiol Date: 2001-12 Impact factor: 4.164
Authors: Tien Yin Wong; Ronald Klein; A Richey Sharrett; Maria I Schmidt; James S Pankow; David J Couper; Barbara E K Klein; Larry D Hubbard; Bruce B Duncan Journal: JAMA Date: 2002-05-15 Impact factor: 56.272
Authors: Tien Yin Wong; Ronald Klein; A Richey Sharrett; Bruce B Duncan; David J Couper; James M Tielsch; Barbara E K Klein; Larry D Hubbard Journal: JAMA Date: 2002-03-06 Impact factor: 56.272
Authors: Tien Yin Wong; Ronald Klein; A Richey Sharrett; F Javier Nieto; Lori L Boland; David J Couper; Thomas H Mosley; Barbara E K Klein; Larry D Hubbard; Moyses Szklo Journal: Stroke Date: 2002-06 Impact factor: 7.914
Authors: Paolo S Silva; Jerry D Cavallerano; Jennifer K Sun; Lloyd M Aiello; Lloyd Paul Aiello Journal: Nat Rev Endocrinol Date: 2010-07-27 Impact factor: 43.330